Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center Double-blind Parallel-group Comparison Study in Involutional Osteoporosis Patients to Examine the Efficacy and Safety of ONO-5920/YM529 Monthly Intermittent Formulation With Its Daily Formulation.

NCT00794443 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00794443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00794443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center Double-blind Parallel-group Comparison Study in Involutional Osteoporosis Patients to Examine the Efficacy and Safety of ONO-5920/YM529 Monthly Intermittent Formulation With Its Daily Formulation.
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2/3
Overall status
Completed
Start date
November 30, 2008
Completion date
April 30, 2010
Enrollment
692 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

bone loss, age-related, osteoporosis